Targeting the endocannabinoid system showed promise for HIV-related nerve pain in preclinical studies and two clinical trials | Research

The takeaway

A systematic review found that preclinical studies consistently support endocannabinoid system modulation for HIV-related neuropathic pain, and two clinical trials showed smoked cannabis was more effective than placebo.

HIV/AIDS clinicians managing neuropathic pain, pain medicine specialists, and researchers developing cannabinoid-based analgesics.

10 of 10 preclinical studies showed ECS-targeting compounds effective for HIV pain

What the researchers found

10 preclinical studies found that endocannabinoids, CB2-selective agonists, and FAAH inhibitors prevented or reversed HIV-associated neuropathic pain. Two completed clinical trials showed smoked cannabis was more effective than placebo. One trial of cannabidivarin (which does not activate cannabinoid receptors) did not reduce HIV neuropathic pain.

Why it matters

HIV-associated neuropathic pain affects many patients and has few effective treatments. This review consolidates evidence that the endocannabinoid system is a viable therapeutic target, with some clinical validation.

The numbers in context

13 studies included. 10 preclinical studies: multiple ECS-targeting compounds effective. 2 clinical trials: smoked cannabis superior to placebo. 1 clinical trial: cannabidivarin not effective. CB2-selective agonists (AM1710, JWH015, JWH133, Gp1a, but not HU308) effective preclinically.

How the study worked

Systematic review searching PubMed, Google Scholar, ClinicalTrials.gov, and EU trial registries for studies on HIV-associated neuropathic pain and endocannabinoid system modulation. 13 articles met inclusion criteria (10 preclinical, 3 clinical).

What this study cannot tell us

Only 3 clinical studies met criteria, all with small samples. Smoked cannabis has significant delivery limitations. The preclinical-to-clinical translation gap remains large. Most preclinical models used antiretroviral-induced rather than virus-induced neuropathy.

How to read the evidence

Systematic review with consistent preclinical results and limited but positive clinical data. Small number of clinical trials limits overall evidence strength.

When this study was published

2021 systematic review covering studies through December 2020.

The bigger picture

HIV-associated neuropathic pain remains undertreated. The consistent preclinical evidence and early clinical support suggest non-psychoactive cannabinoid-based treatments could eventually become options, particularly CB2 agonists and FAAH inhibitors.

Questions still open

Could non-smoked cannabis formulations (oral, topical) be effective for HIV neuropathic pain? Would CB2-selective agonists provide pain relief without psychoactive effects in patients? How do antiretroviral regimen changes affect the need for pain treatment?

Common questions

Does cannabis help HIV-related nerve pain?

Two clinical trials found smoked cannabis more effective than placebo for HIV neuropathic pain. However, a non-receptor-activating cannabinoid (cannabidivarin) was not effective, suggesting cannabinoid receptor activation is needed.

Are there non-psychoactive options?

Preclinical studies showed CB2-selective agonists and FAAH inhibitors were effective. These would not produce a "high" and are being developed for potential clinical use, though no clinical trials have been completed yet.

Read the original research

Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.

IBRO neuroscience reports, 10, 109-118

View on PubMed ↗Publisher’s paper ↗

Citation

Aly, Esraa; Masocha, Willias. (2021). Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.. IBRO neuroscience reports, 10, 109-118. https://doi.org/10.1016/j.ibneur.2021.01.004